Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-01
2008-07-01
Mondesi, Robert B. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S078040
Reexamination Certificate
active
10069613
ABSTRACT:
The present invention relates to a method of producing a bioactive peptide, wherein the peptide is 7 to 25 amino acids in length, has at least 3 cationic amino acids and is capable of forming an amphipathic α-helix, which method comprises identification of a cationic sector and division of the remaining part of the peptide into three further sectors which are substantially equal in size, and incorporation of at least 60% of the bulk and lipophilicity provided by the amino acid R groups into the sectors flanking the cationic sector; and to uses of the peptides produced thereby in therapy, particularly in the treatment of benign or malignant tumours.
REFERENCES:
patent: 2003/0022821 (2003-01-01), Svenden et al.
patent: WO 96/31537 (1996-10-01), None
patent: WO 98/06425 (1998-02-01), None
patent: WO 98/33509 (1998-08-01), None
Noble, M. and Dietrich, J. Trends in Neuroscience vol. 27, No. 3, pp. 148-154 Mar. 2004.
Rekdal et al. Journal of Peptide Science 5: 32-45 (Jan. 1999). “Construction and Synthesis of Lactoferricin Derivatives with Enhanced Antibacterial Activity”.
Javadpour, M. M. et al., “De Novo Antimicrobial Peptides with Low Mammalian Cell Toxicity,”J. Med. Chem., 1996, pp. 3107-3113, vol. 39. American Chemical Society.
Johnstone, S.A. et al., “In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin agains,t wild-type and p-glycoprotein over-expressing tumor cell lines,”Anti-Cancer Drug Design, 2000, pp. 151-160, vol. 15. Oxford University Press.
Shafer, W.M., et al., “Bactericidal Activity of a Synthetic Peptide (CG 117-136) of Human Lysosomal Cathepsin G Is Dependent on Arginine Content,”Infection and Immunity, Nov. 1996, pp. 4842-4845, vol. 64, No. 11. American Society for Microbiology.
Alvarez-Bravo, J., et al., “Novel synthetic antimicrobial peptides effective against methicillin-resistantStaphylococcus aureus,” Biochem J., 1994, pp. 535-538, vol. 302. Great Britain.
Dathe, M., et al., “Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells,”Biochimica et Biophysica Acta, 1999, pp. 71-87, vol. 1462. Elsevier.
Jones, M.K., et al., “Computer programs to identify and classify amphipathic α helical domains,”Journal of Lipid Research, 1992, pp. 287-296, vol. 33.
Dathe, M., et al., “Hydrophobicitiy, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphiphatic helical peptides,”FEBS Letters, 1997, pp. 208-212, vol. 403.
Peck-Miller, K.A., “Structure-activity analysis of the antitumor and hemolytic properties of the amphiphilic α-helical peptide, C18G,”Int. J. Peptide Protein Res., 1994, pp. 143-151, vol. 44. Belgium.
Maloy, W.L. et al., “Structure-Activity Relationship Studies Around a Decapeptide in Order to Improve Its Therapeutic Index.” Poster Extract (P400) from 25thEuropean Peptide Symposium.
Rekdal Øystein
Solstad Terese
Svendsen John Sigurd
Wikman Mari
Yang Nannan
Desai Anand U
Lytix Biopharma
Mondesi Robert B.
Rothwell Figg Ernst & Manbeck
LandOfFree
Methods of peptide preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of peptide preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of peptide preparation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3936368